RxDoctor Payments Data

David Valenzuela, MD

Family Medicine · Las Cruces, NMNPI 1487627246

Payments from drug & device makers

$998in general payments, 2019–2025

Across 33 payments — averaging $30.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$343
  • Novo Nordisk$220
  • Amarin Pharma, Inc.$100
  • Abiomed$99
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$78
  • Lilly USA, LLC$45
  • plus $113 from 7 others

What the payments were for

  • Food & beverage$998100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$998 in reported general payments places this provider in the 80th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$97,536
Medicare patients
119
Services billed
1,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$101,229
JardianceEmpagliflozin43$48,200
TrulicityDulaglutide17$25,040
RybelsusSemaglutide11$23,033
JanuviaSitagliptin Phosphate15$21,246
FarxigaDapagliflozin Propanediol12$16,489
MounjaroTirzepatide12$14,806
SymbicortBudesonide/Formoterol Fumarate28$6,448
MyrbetriqMirabegron12$6,298
Testosterone26$4,541
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,807
Advair DiskusFluticasone Propion/Salmeterol13$3,479
Potassium Chloride56$2,664
Raloxifene Hcl53$2,202
Rosuvastatin Calcium178$2,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$220$124,26270 claims
Lilly USA, LLCTrulicity, Mounjaro$45$39,84629 claims
AstraZenecaFarxiga, Symbicort$343$22,93740 claims
MerckJanuvia$19$21,24615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →